Synephrine HCL
description1
description2
Basic information
Product Name: Synephrine HCL
IUPAC Name: (R)-4-[1-Hydroxy-2-(methylamino)ethyl]phenol hydrochloride
CAS No.: 5985-28-4
Molecular Formula: C₉H₁₃NO₂·HCl
Physicochemical Properties:
Parameter |
Value/Description |
Appearance |
White crystalline powder |
Melting Point |
184-188°C (decomposition) |
Solubility |
Highly water-soluble (50 mg/mL), slightly soluble in ethanol |
Predicted logP |
0.5 (relatively hydrophilic) |
Stability |
Light- and moisture-sensitive; most stable at pH 3-6 |
Quality Standard: CP2020,JP,Customer Made
Specification
Test Items |
Standard |
Synephrine HCL (CAS: 5985-28-4) |
98% by HPLC |
Loss on drying |
≤0.5% |
Residue on ignition |
≤0.5% |
Natural Source
Dual Action
Regulatory Status
1. Receptor Selectivity
β-3 Receptor Dominance
Activates adipocyte cAMP-PKA pathway → phosphorylates hormone-sensitive lipase (HSL) → hydrolyzes triglycerides.
Avoids α-1 Effects
Low affinity for vascular α-1 receptors (Ki >10 μM), minimizing blood pressure fluctuations.
2. Pharmacokinetics
Absorption
~80% oral bioavailability (fasted), Tₘₐₓ = 1-2 hours.
Metabolism
Metabolized by MAO and COMT enzymes; half-life = 2-3 hours.
Excretion
90% excreted unchanged in urine.
Oral Use
Weight loss: 50-100 mg/day, divided into morning and afternoon doses.
Pre-exercise: 100 mg single dose; avoid evening intake (risk of insomnia).
Contraindicated Combinations
MAO inhibitors (risk: hypertensive crisis).
Caffeine (may synergistically increase heart rate).
Safety Evaluation
1. Adverse Reactions
Reaction |
Incidence |
Management |
Palpitations |
5-8% |
Reduce dose or discontinue |
Headache |
3-5% |
Hydrate and rest |
GI Discomfort |
2-4% |
Take with food |
2. Contraindications
Severe cardiovascular disease (e.g., arrhythmias, uncontrolled hypertension).
Pregnancy (insufficient safety data).
Research Progress Green max
Metabolic Syndrome Therapy:
Phase II trials show 22% improvement in insulin sensitivity (HOMA-IR↓).
Extended-Release Formulations:
Microsphere technology extends duration to 8-10 hours.
Neuroprotective Potential:
Animal models demonstrate reduced ischemic brain injury (mechanism unclear).
Please Send me email and you can get more what you want.
Such as product of Price, Specification, MOA, MSDS, Flow Chart, Packing details, Shipping Term, Payment Term, after Sale service and so on.
Our experts will solve them in no time.